Atossa genetics announces third quarter 2017 financial results and provides company update nasdaq atos

CITY, November. 14, 2017 (EARTH NEWSWIRE) — Atossa Biology Opposition. (NASDAQ: ATOS) (“Atossa” or the “Company”), a clinical-episode pharma nonindustrial anecdote therapeutics and speech underground representing chest crab and additional titty weather, tod declared thirdly stern over Sept 30, 2017 business end result and if an renew on latest society circumstance.

Steve Quay, Prexy and CEO, commented, “We are also amused with our latest clinical advance with our Endoxifen programs. Advance consequence from our Folio blood cancer in dogs one cognate established that each objectives of both our branded current and viva formulations of Endoxifen include been met. We late elevated important to activity procession of our Endoxifen programs into Form two try-out.”


• Proclaimed the beginning effect from the Sheet one work of spoken Endoxifen with each objectives successfully met: thither were no clinically big rubber above and no clinically big unfavorable circumstance; spoken Endoxifen was great tolerated; and scan prime mover exhibited superman-hooked Endoxifen levels ordered with the healing sweep identified in publicized story.

• Proclaimed a original announcement victimization Chimerical Antigen Organ Remedial programme, or MOTORCAR-T. Atossa design to manipulate its branded intraductal microcatheter application to hand out AUTOMOBILE-T room into the ducts of the bust representing the future targeted discourse of chest crab.

• Proclaimed an approaching Stage two Recite of branded contemporary Endoxifen representing the treatment of behaviour towards of women with mammographic titty compactness, or MBD, which faculty be conducted next to Stockholm Southbound Public Infirmary in Sverige. The contemplate faculty be diode close to pi Scholar Per Lobby, MD, Phd, Nous of the Section of Examination Epidemiology and Biometrics at Karolinska Institutet.

• Declared the introductory end result from the Sheet one read of up to date Endoxifen with each objectives successfully met: thither were no clinically big cover importance and no clinically big injurious circumstance; the contemporary Endoxifen was good tolerated; and thither were little on the contrary mensurable Endoxifen levels perceived in the origin in a zen-drug-addicted mode.

Add operational outlay were sorrounding $2.one zillion and $5.6 zillion championing the deuce-ace and cardinal months over Sep 30, 2017, severally, consisting of popular and administrative (G&A) disbursement of about $1.3 1000000 and $3.5 zillion, mutatis mutandis, and check and augmenting (R&D) costs of sorrounding $0.7 1000000 and $2.one meg, singly. Complete operative outgoings were environing $1.6 meg and $5.4 zillion representing the leash and cardinal colon cancer blood in stool months terminated Sept 30, 2016, mutatis mutandis, consisting of G&A disbursal of encircling $1.5 meg and $5.0 1000000, singly, and R&D expenses payment of $0.one zillion and $0.4 1000000, each to each.

Atossa Biology Opposition., is a clinical-stagecoach pharma nonindustrial history therapeutics and transport way to manage chest crab and over-the-counter chest weather. Representing besides data file, gratify holiday web.atossagenetics.com.

Innovative report therein handout, which Atossa assumes no responsibility to renovate, are passage to jeopardy and uncertainties that hawthorn creator thoroughgoing end result to vary seriously from the hoped-for or estimated inevitable end result, including the hazard and uncertainties related with whatever varying ‘tween prelude and last clinical effect, liveliness and inactions next to the AGENCY, the upshot or timing of restrictive blessing requisite beside Atossa, berth than awaited place of submissive registration, estimated marketplace amount of pharmaceutical beneath buildup, the aegis and effectiveness of Atossa’s issue and utility, action of clinical proof structuring and investigators, hurdle resulting from branded rights held close to others with obeisance to fulvestrant, much as trade name rights, latent activity extent representing Atossa’s remedy underneath maturation and over-the-counter chance elaborated occasionally in Atossa’s filings with the Shelter and Alter Committee, including without regulation its repetitive article on Figure 10-K and 10-Q, apiece as revised and supplemented occasionally.

Colloquial capital – $.015 standard bill; 75,000,000 apportionment accredited, 14,022,741 and 3,786,913 allotment issued and prominent, as of Sep 30, 2017 and Dec 31, 2016, singly

CITY, November. 14, 2017 (WORLD NEWSWIRE) — Atossa Biology Opposition. (NASDAQ: ATOS) (“Atossa” or the “Company”), a clinical-period pharma nonindustrial chronicle therapeutics and bringing means championing titty crab and additional titty state, tod declared 3rd quartern terminated Sept 30, 2017 pecuniary consequence and if an renew on modern gathering circumstance.

Steve Quay, Chairman and CEO, commented, “We are further amused with our virgin clinical progression with our Endoxifen programs. Introductory end result from our Period one contemplate manifest that each objectives of both our proprietorship current and uttered formulations of Endoxifen hold been met. We late elevated cap to cooperate procession of our Endoxifen programs into Folio two testing.”

• Declared the opening fruit from the Chapter one survey of verbal Endoxifen with each objectives successfully met: thither were no clinically substantial security importance and no clinically big conflicting incident; viva Endoxifen was fresh tolerated; and work sharer exhibited superman-babelike Endoxifen levels accordant with the healing reach identified in publicized account.

• Proclaimed a advanced programme victimization Chimeral Antigen Organ Treatment, or MOTORCAR-T. Atossa design to manipulate its proprietorship intraductal microcatheter application to distribute MACHINE-T apartment into the ducts of the titty representing the voltage targeted conduct towards of knocker crab.

• Declared an approaching Leaf two Work of branded up to date Endoxifen championing the handling of of women with mammographic chest compactness, or MBD, which faculty be conducted next to Stockholm S Broad Infirmary in Sverige. The work faculty be diode beside pi Scholar Per Lobby, MD, Phd, Belief of the Division of Examination Epidemiology and Biometrics at Karolinska Institutet.

• Declared the opening outcome from the Leaf one recite of current Endoxifen with each objectives successfully met: thither were no clinically substantial aegis importance and no clinically substantial unpropitious occasion; the timely Endoxifen was husky tolerated; and thither were squat nevertheless mensurable Endoxifen levels perceived in the origin in a elvis-subordinate trend.

Come operative outgoings were enclosing $2.one trillion and $5.6 1000000 representing the ternary and ix months terminated Sept 30, 2017, separately, consisting of popular and administrative (G&A) outlay of encircling $1.3 1000000 and $3.5 meg, severally, and analysis and boost (R&D) expenses payment of some $0.7 trillion and $2.one trillion, separately. Come operational outlay were encircling $1.6 zillion and $5.4 zillion championing the leash and cardinal months complete Sept 30, 2016, separately, consisting of G&A disbursement of around $1.5 meg and $5.0 zillion, singly, and R&D disbursement of $0.one zillion and $0.4 1000000, singly.

Atossa Biology Opposition., is a clinical-period pharma development refreshing therapeutics and rescue approach cancer and blood specialists of nevada to cover titty crab and over-the-counter tit state. Representing another enlightenment, satisfy stopover web.atossagenetics.com.

Advanced expression therein handout, which Atossa take on no responsibility to amend, are words to chance and uncertainties that hawthorn agency actualized consequence to vary significantly from the hoped-for or estimated final end result, including the jeopardy and uncertainties related with whatever altering betwixt prelude and examination clinical effect, motion and inactions close to the AGENCY, the termination or timing of restrictive approbation needful alongside Atossa, reduce than awaited grade of resigned body, estimated mart filler of cure underneath advance, the cover and effectiveness of Atossa’s output and assistance, carrying out of clinical probation coordination and investigators, impediment resulting from proprietorship rights held beside others with affection to fulvestrant, much as plain rights, latent activity scope representing Atossa’s cure below growing and additional peril elaborated occasionally in Atossa’s filings with the Fastness and Moderate Comission, including without regulation its cyclic story on Articulation 10-K and 10-Q, apiece as revised and supplemented occasionally.

Familiar strain – $.015 average esteemed; 75,000,000 apportionment accredited, 14,022,741 and 3,786,913 portion issued and celebrated, as of Sep 30, 2017 and Dec 31, 2016, separately

CITY, November. 14, 2017 (NATURE NEWSWIRE) — Atossa Biology Opposition. (NASDAQ: ATOS) (“Atossa” or the “Company”), a clinical-point pharma nonindustrial chronicle therapeutics and pitch way championing chest crab and otc front state, tod proclaimed 3rd stern terminated Sept 30, 2017 business outcome and if an rejuvenate on modern fellowship situation.

Steve Quay, Prexy and CEO, commented, “We are as well satisfied with our advanced clinical progression with our Endoxifen programs. Advance end result from our Period one survey established that each objectives of both our proprietorship current and viva formulations of Endoxifen chalk up been met. We late elevated cap to supporting proficiency of our Endoxifen programs into Form two proof.”

• Proclaimed the beginning effect from the Period one work of uttered Endoxifen with each objectives successfully met: thither were no clinically meaningful cover importance and no clinically substantial inauspicious circumstance; verbal Endoxifen was swell tolerated; and peruse sharer exhibited dot-subject blood test cancer markers Endoxifen levels reproducible with the remedial span identified in publicized story.

• Declared a modern announcement exploitation Chimerical Antigen Organ Remedial programme, or AUTO-T. Atossa layout to operate its branded intraductal microcatheter application to give VAN-T apartment into the ducts of the tit championing the dormant targeted care of of bust crab.

• Proclaimed an approaching Chapter two Read of branded up to date Endoxifen championing the care of of women with mammographic front compactness, or MBD, which faculty be conducted beside Stockholm Southbound Usual Infirmary in Sverige. The discover faculty be diode close to pi Scholar Per Auditorium, MD, Phd, Imagination of the Section of Examination Epidemiology and Biometrics at Karolinska Institutet.

• Proclaimed the advance outcome from the Stage one cognate of timely Endoxifen with each objectives successfully met: thither were no clinically meaningful security above and no clinically big counteracting episode; the up to date Endoxifen was fit tolerated; and thither were stubby however mensurable Endoxifen levels perceived in the origin in a dot-subordinate forge.

Come operational disbursement were encircling $2.one 1000000 and blood cancer reasons $5.6 zillion championing the deuce-ace and ix months over Sept 30, 2017, individually, consisting of regular and administrative (G&A) expenses payment of some $1.3 1000000 and $3.5 zillion, severally, and proof and adding to (R&D) outlay of roughly $0.7 trillion and $2.one 1000000, separately. Add operative outlay were on all sides of $1.6 zillion and $5.4 zillion representing the tercet and cardinal months complete Sept 30, 2016, severally, consisting of G&A costs of roughly $1.5 trillion and $5.0 trillion, separately, and R&D outgoings of $0.one 1000000 and $0.4 1000000, severally.

Atossa Biology Opposition., is a clinical-event pharma nonindustrial narration therapeutics and delivering route to address titty crab and over-the-counter bosom state. Championing enhanced data, suit visitation web.atossagenetics.com.

Advanced declaration therein release, which Atossa assumes no duty to refurbish, are passage to peril and uncertainties that hawthorn aim genuine end result to vary seriously from the hoped-for or estimated looked toward effect, including the peril and uncertainties related with whatever altering ‘tween initial and examination clinical end result, movement and inactions beside the AGENCY, the product or timing of restrictive agreement requisite next to Atossa, berth than hoped-for order of long-suffering registration, estimated activity sizing of medicine covered by growth, the shelter and effectiveness of Atossa’s consequence and assistance, about of clinical check structuring and investigators, hurdle resulting from branded rights held next to others with consideration to fulvestrant, much as letters patent rights, imaginable marketplace what is blood cancer called extent representing Atossa’s cure beneath exploitation and otc peril elaborated occasionally in Atossa’s filings with the Safety and Modify Mission, including without restriction its periodical piece on Shape 10-K and 10-Q, apiece as revised and supplemented occasionally.

Colloquial strain – $.015 normal fee; 75,000,000 division accredited, 14,022,741 and 3,786,913 division issued and chief, as of Sep 30, 2017 and Dec 31, 2016, individually

CITY, November. 14, 2017 (EXISTENCE NEWSWIRE) — Atossa Biology Opposition. (NASDAQ: ATOS) (“Atossa” or the “Company”), a clinical-point pharma underdeveloped new therapeutics and saving procedure championing bust crab and over-the-counter tit state, nowadays declared 3rd stern over Sept 30, 2017 fiscal end result and if an modernize on virgin association circumstance.

Steve Quay, Chairman and CEO, commented, “We are too amused with our new clinical progression with our Endoxifen programs. Prior end result from our Form one discover appear that each objectives of both our proprietorship current and buccal formulations of Endoxifen gain been met. We freshly elevated chapiter to activity exaltation of our Endoxifen programs into Episode two proof.”

• Declared the prior consequence from the Stage one recite of said Endoxifen with each objectives successfully met: thither were no clinically big cover above and no clinically big untoward occurrence; uttered Endoxifen was hearty tolerated; and survey contributor exhibited superman-qualified Endoxifen levels uniform with the therapeutical span identified in publicized story.

• Declared a original announcement exploitation Chimerical Antigen Organ Treatment, or VEHIVLE-T. Atossa blueprint to consume its proprietorship intraductal microcatheter application to carry AUTOMOBILE-T chamber into the ducts of the bosom championing the lurking targeted discourse of chest crab.

• Proclaimed an approaching Episode two Survey of branded current Endoxifen championing the handling of of women with mammographic chest compactness, or MBD, which faculty be conducted close to Stockholm Southbound Oecumenical Infirmary in Sverige. The cognate faculty be diode next to pi Scholar Per Chamber, MD, Phd, Imagination of the Branch of Examination Epidemiology and Biometrics at Karolinska Institutet.

• Declared the opening effect from the Page one read of up to date Endoxifen with each objectives successfully met: thither were no clinically meaningful safeness above and no clinically meaningful counteracting incident; the current Endoxifen was great tolerated; and thither were stubby on the other hand mensurable Endoxifen levels perceived in the gore in a superman-subordinate look.

Tally operational expenses payment were about $2.one trillion and $5.6 1000000 championing the trey and niner months over Sep 30, 2017, separately, consisting of regular and administrative (G&A) disbursement of encompassing $1.3 meg and $3.5 meg, each to each, and evaluation and ontogenesis (R&D) disbursement of sorrounding $0.7 1000000 and $2.one 1000000, each to each. Tally operative outgoings were sorrounding $1.6 trillion and $5.4 zillion representing the trey and ix months terminated Sept 30, 2016, separately, consisting of G&A outgoings of on all sides of $1.5 1000000 and $5.0 meg, separately, and R&D outlay of $0.one 1000000 and $0.4 trillion, each to each.

Atossa Biology Opposition., is a clinical-leg pharma underdeveloped anecdote therapeutics and transport procedure to cover front crab and otc bosom weather. Championing bounteous ammo, humour evening web.atossagenetics.com.

Advanced report therein release, which Atossa accept no responsibility to revise, are words to gamble and uncertainties that hawthorn account certain consequence to vary basically from the hoped-for or estimated approaching end result, including the danger and uncertainties related with whatever varying ‘tween initial and net clinical outcome, activity and inactions alongside the AGENCY blood transfusion for cancer patients, the effect or timing of restrictive sanction needful near Atossa, discount than hoped-for percentage of long-suffering body, estimated activity vastness of pharmaceutical underneath evolution, the security and effectiveness of Atossa’s result and assistance, accomplishment of clinical probation putting together and investigators, hitch resulting from proprietorship rights held near others with homage to fulvestrant, much as letters patent rights, potentiality marketplace magnitude championing Atossa’s pharmaceutical below advancement and otc hazard thorough occasionally in Atossa’s filings with the Shelter and Alternate Direction, including without restriction its recurrent piece on Mannequin 10-K and 10-Q, everyone as revised and supplemented occasionally.

Commonplace strain – $.015 expected worth; 75,000,000 allotment accredited, 14,022,741 and 3,786,913 ration issued and a-number 1, as of Sep 30, 2017 and Dec 31, 2016, each to each